מודרנה מכריזה על הצלחה של חיסון נגד סרטן – ומתפוצצת בבורסה

הערכה

Moderna's stock more than doubled in pre-market trading after reporting a successful trial for a skin cancer vaccine. The trial combined Moderna's mRNA technology with Merck's Keytruda and showed a significant improvement in preventing melanoma recurrence across over 1,100 patients. Merck shares also rose 8%. This positions mRNA technology beyond infectious disease applications, potentially opening a massive new market. Investors are betting this is not a one-off result but a platform breakthrough. The real test comes when full trial data is published and regulatory scrutiny begins.